Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai Licenses KRAS-Targeting Drug to Verastem
January 10, 2020
- Keytruda Remains Top-Seller in December Drug Ranking in Japan: Encise
January 10, 2020
- Hisamitsu Starts 2 PIII Studies for NSAIDs Patch, Plans Filing by February 2022
January 10, 2020
- Bristol-Myers Japan Chief Doubles as Celgene President amid Transition
January 10, 2020
- US District Court Dismisses Asahi Kasei’s Request for Continuing Supply of Xiaflex
January 10, 2020
- Meiji Gains Japan Rights for Novel Blood Cancer Treatment from HUYA Bioscience
January 10, 2020
- Keytruda Top New Sales Generator in 2020, Enhertu Seen as Biggest Arrival: Evaluate
January 9, 2020
- Kyowa Kirin Seeks Add’l Indication for Lumicef
January 9, 2020
- Mitsubishi Chemical to Purchase 197 Million Shares of Mitsubishi Tanabe, Taking Over 90% Ownership
January 9, 2020
- ASKA Grabs Japan, South Korea Rights to Insud’s Oral Contraceptive
January 9, 2020
- Promethera Kicks Off PIIb Study of Cell-Based Therapy HepaStem for ACLF in Europe
January 9, 2020
- Chugai Chairman Pushes for Industry Shakeup, Govt Initiative to Develop Ecosystem
January 8, 2020
- Daiichi Sankyo’s Blockbuster Hopeful Enhertu Hits US Market
January 8, 2020
- Meiji Seika Forms JV with US Startup to Develop, Commercialize cGVHD Treatment
January 8, 2020
- Kyorin Grabs Japan Rights to aTyr’s Immunomodulator
January 7, 2020
- Taiho, Astex in KRAS Licensing Deal with US Merck
January 7, 2020
- Kyowa Kirin’s Parkinson’s Med Accepted for Review in Europe
January 7, 2020
- Eisai’s Fycompa Now Available in China
January 7, 2020
- Ono, Seikagaku File Novel Osteoarthritis Treatment in Japan
January 7, 2020
- Sumitomo Dainippon Closes US$3 Billion Roivant Deal
January 7, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…